ABOUT™—Perceived Risk (formally Perceived Risk Instrument - PRI) (ABOUT™—Perceived Risk)

Data regarding development and initial validation studies have been published in peer-reviewed journals. The original name of the instrument was Perceived Risk Instrument (PRI), Personal version (PRI-P) and General version (PRI-G). The name was changed later to ABOUT™—Perceived Risk. The acronym PRI is kept in the description of the measurement properties to respect the original reference.

Background:

Philip Morris has launched an ongoing collaborative effort to develop fit-for-purpose measurement instruments (i.e., concept-driven instruments providing interpretable outcomes for the purpose intended) to enhance the scientific framework of harm reduction. This new initiative has resulted in the creation of the ABOUT™ Toolbox (Assessment of Behavioral OUtcomes related to Tobacco and nicotine products).
The ABOUT™ Toolbox currently comprises five measurement instruments that are at various stages of development and validation

The ABOUT™—Perceived Risk has been developed as a self-report instrument designed to assess the perceived risks associated with the use of tobacco and nicotine-containing products, including Conventional Cigarettes (CCs), Nicotine Replacement Therapy products (NRTs), and Reduced Risk Products (RRPs*). The ABOUT™—Perceived Risk can also be used to assess the perceived risks associated with the past use of CC (e.g., ‘Cessation’).
By quantifying perceived tobacco and nicotine-containing product risks, the ABOUT™—Perceived Risk may be used by researchers in clinical and population-based studies to gather meaningful insight on 1) the effects of risk perception on tobacco and nicotine-containing product use behavior among current tobacco users, 2) the effects on product use initiation among non-users, and 3) the effects of risk communication on consumers’ understanding and perceptions.

The ABOUT™—Perceived Risk has been developed to assess two sets of perceptions:
1) the perceived risks to the individual respondent (personal risk);
and
2) the perceived risks to users of the product in general (general risk).
 
The two versions share the same items and response options; only the opening stems differ so that it orients respondents to respond with regards to their personal risk or the risks to the average user of the product.
 
 
* Reduced-Risk Products (“RRPs”) is the term PMI S.A. use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking.  PMI S.A. has a range of RRPs in various stages of development, scientific assessment and commercialization.  Because RRPs do not burn tobacco, they produce far lower quantities of harmful and potentially harmful compounds than found in cigarette smoke.
More details are available on www.pmiscience.com

Cano S, Chrea C, Salzberger T, Alfieri T, Emilien G, Mainy N, Ramazzotti A, Lüdicke F, Weitkunat R. Development and validation of a new instrument to measure perceived risks associated with the use of tobacco and nicotine-containing products. Health Qual Life Outcomes. 2018 Sep 21;16(1):192 (Full Text Article)

Salzberger T, Chrea C, Cano S, Martin M, Atkison M, Emilien G, Mainy N, Ramazzotti A, Weitkunat R, Lüdicke F. Perceived risks associated with the use of tobacco and nicotine-containing products: Findings from qualitative research. Tobacco Science & Technology. 2017 Dec; 50(13): 32-42 (Full Text Article)

• ABOUT™—Perceived Risk User agreement

* Excluding VAT
Commercial users: Industry, CRO, any for-profit companies
Funded Academic research: Projects receiving funding from commerce, government, EU or registered charity. Funded academic research– sponsored by industry fits the “commercial users” category.
Not funded academic users, individual medical practice: Projects are not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds

Conditions to translate

Please refer to the "Languages" tab

Conditions to implement in electronic applications

Exclusive licensor for e-versions of the questionnaire: Mapi Research Trust

Academic and Commercial Users

• Shall follow the “Conditions of use”  mentioned above
• In addition, in case the electronic version of the questionnaire is developed by a third party (IT Company, e-PRO vendor…), User shall check with Mapi Research Trust that this third party has signed the necessary License Agreement with Mapi Research Trust before developing the electronic version of the Questionnaire.

Information Technology (IT) Companies (incl. ePRO vendors)

• In case of a one-shot development and commercial use of an electronic version of the questionnaire by the IT Company, the IT Company shall:
  • Sign a “Specific-Study License Agreement with IT Company” with Mapi Research Trust
    • authorizing the electronic implementation of the questionnaire for the specific study only
    • shall not permit the IT Company to promote the electronic version of the questionnaire or its use for another study or another client
  • Pay a one-shot license fee per study to Mapi Research Trust: 500 Euros
• In case of an IT Company who wishes to develop an electronic version of the questionnaire and would like to obtain a non-exclusive license to market and promote their devices / tablets / smartphones / e-applications using the questionnaire, the IT Company shall:
  • Sign a “General License Agreement with IT Company” with Mapi Research Trust
    • authorizing the electronic implementation of the questionnaire on multiple devices for multiple studies and clients
    • permitting the IT Company to promote the electronic versions of the questionnaire by any marketing means (including, but not limited to, IT Company’s  promotional documents / websites / press release / communication during conferences / webinars)
  • Pay an annual administrative fee of 2,500 Euros to Mapi Research Trust
  • Pay an annual royalty fee of 2,500 Euros to the author(s)

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

• ABOUT™—Perceived Risk |in English for USA

The listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.

My study is not funded

• I am a non-commercial user
• I do not receive specific funding for my study
• I intend to use the questionnaire in individual clinical practice or research study